2nd Quarter - Report

AMERICAN SOCIETY FOR CLINICAL PATHOLOGY for AMERICAN SOCIETY FOR CLINICAL PATHOLOGY

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$45,000
Expense method
B: tax-exempt organisations, Internal Revenue Code section 6033(b)(8)

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report (this page) Jul 23, 2025 $45,000 Replaced
2nd Quarter - Report Jul 23, 2025 $45,000 Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Labor Issues/Antitrust/Workplace LBR

Physician, clinical laboratory professional, and allied health workforce issues, Federal Funding for Education, Student loan Repayment/Forgiveness, and Related Workforce Development; Workforce Reinvestment Act; Federal Healthcare Workforce Issues; Appropriations for Federal Agencies; Clinical Laboratory Improvement Amendments; COVID-19 Response and Laboratory Test Capacity

LobbyistCovered position, as disclosed
MATTHEW SCHULZE —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); SENATE; Veterans Affairs, Dept of (VA); Health Resources & Services Administration (HRSA); Food & Drug Administration (FDA); Centers For Disease Control & Prevention (CDC); Education, Dept of

Health Issues HCR

Medicare; Electronic Health Records/Health Information Technology; Medicare Access and CHIP Reauthorization; Protecting Access to Medicare Act; Medicare Physician and Clinical Laboratory Fee Schedules; Medicare Quality Payment Program; Stark Self-Referral Reform; Physician and Clinical Laboratory Personnel Shortages/workforce issues; Education and Loan Repayment Programs; Appropriations for Federal Agencies; Global Health Initiative; Laboratory Access for Beneficiaries Act; Clinical Laboratory Improvement Amendments ; COVID-19 Response and Laboratory Testing Capacity; Communicable Diseases and Pandemic Preparedness; federal oversight of laboratory tests including laboratory developed testing services

LobbyistCovered position, as disclosed
MATTHEW SCHULZE —

Contacted: Food & Drug Administration (FDA); Veterans Affairs, Dept of (VA); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC)

Medical/Disease Research/Clinical Labs MED

Medicare; Electronic Health Records/Health Information Technology; Medicare Access and CHIP Reauthorization; Protecting Access to Medicare Act; Medicare Physician and Clinical Laboratory Fee Schedules; Medicare Quality Payment Program; Medicare National and Local Coverage Determinations; Federal Oversight of Laboratory Tests including Laboratory Developed Testing Services; Physician and Clinical Laboratory Personnel Shortages/workforce issues; Education and Loan Repayment Programs; Appropriations for Federal Agencies; Global Health Initiative; Laboratory Access for Beneficiaries Act; Clinical Laboratory Improvement Amendments; Laboratory oversight; COVID-19 Response and Laboratory Testing Capacity; Communicable Diseases and Pandemic Preparedness; Stark Self-Referral Reform

LobbyistCovered position, as disclosed
MATTHEW SCHULZE —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Veterans Affairs, Dept of (VA); Centers For Disease Control & Prevention (CDC)

Medicare/Medicaid MMM

Medicare; Electronic Health Records/Health Information Technology; Medicare Access and CHIP Reauthorization; Protecting Access to Medicare Act; Medicare Physician and Clinical Laboratory Fee Schedules; Medicare Quality Payment Program; Medicare National and Local Coverage Determinations; Federal Oversight of Laboratory Tests including Laboratory Developed Testing Services; Physician and Clinical Laboratory Personnel Shortages/workforce issues; Education and Loan Repayment Programs; Appropriations for Federal Agencies; Global Health Initiative; Laboratory Access for Beneficiaries Act; Clinical Laboratory Improvement Amendments; Laboratory oversight; COVID-19 Response and Laboratory Testing Capacity; Communicable Diseases and Pandemic Preparedness; Stark Self-Referral Reform

LobbyistCovered position, as disclosed
MATTHEW SCHULZE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); Bureau of Labor Statistics (BLS); Centers For Medicare and Medicaid Services (CMS); Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.